Pfizer on Monday announced that its COVID-19 vaccine has proven effective in preventing infection in over 90% of Phase 3 clinical trial patients, and added that it could have 50 million doses available by year-end. Dan talks to Pfizer CEO Albert Bourla about data, distribution, politics, and how he reacted upon receiving the news.